DDInter385 DDInter1294
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Cisapride {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nitisinone
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Cisapride {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Nilutamide
Cisapride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) interacts with {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Nilutamide
Cisapride {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Nilutamide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Androgen Receptor Antagonists {u} (Pharmacologic Class) includes {v} (Compound) Nilutamide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Bicalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Nilutamide
Cisapride may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) resembles Nilutamide (Compound)
Cisapride (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone (Compound) resembles Nilutamide (Compound)
Cisapride (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide (Compound) resembles Nilutamide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Nilutamide (Compound)
Cisapride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) interacts with POR (Gene) and POR (Gene) is bound by Nilutamide (Compound)
Cisapride (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Nilutamide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide (Compound) resembles Nilutamide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class) and Androgen Receptor Antagonists (Pharmacologic Class) includes Nilutamide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Nilutamide (Compound)